Pharmacokinetics of pirmenol enantiomers and pharmacodynamics of pirmenol racemate in patients with premature ventricular contractions

Journal of Clinical Pharmacology

Volumn 37, Issue 6, 1997, Pages 502-513

  Janiczek, Nancy ^a,b   Smith, David E ^a,b   Chang, Tsun ^b   Sedman, Allen J ^b   Stringer, Kathleen A ^c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b PFIZER INC   (United States)

^c MILLARD FILLMORE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; PIRMENOL;

ADULT; AGED; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; ENANTIOMER; FEMALE; HEART VENTRICLE EXTRASYSTOLE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PHARMACOKINETICS; RACEMIC MIXTURE;

EID: 0030953227     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1997.tb04328.x     Document Type: Article

References (44)

1. Hammill SC, Shand DG, Routledge PA, Hindman MC, Baker JT, Pritchett ELC: Pirmenol, a new antiarrhythmic agent: initial study of efficacy, safety and pharmacokinetics. Circulation 1982;65:369-375.
2. Lee TG, Goldberg AD, Chang T, Serkland MT, Yakatan GJ, Johnson EL, et al: Pharmacokinetics and efficacy of pirmenol hydrochloride in the treatment of ventricular dysrhythmia. J Cardiovasc Pharmacol 1983;5:632-637.
3. Stringer KA, Cetnarowski AB, Goldfarb A, Lebsack ME, Chang T, Sedman AJ: Enhanced pirmenol elimination by rifampin. J Clin Pharmacol 1988;8:1094-1097.
4. Hammill SC, Shand DG, Harrell FE, Zimmerman JM, Reiter MJ, Verghese C, Pritchett ELC: Pirmenol kinetics and effective oral dose. Clin Pharmacol Ther 1982;32:686-691.
5. Anderson JL, Lutz JR, Sanders SW, Nappi JM: Efficacy of intravenous pirmenol hydrochloride for treatment of ventricular arrhythmias: a controlled comparison with lidocaine. J Cardiovasc Pharmacol 1983;5:213-220.
6. Sanders SW, Nappi JM, Foltz RL, Lutz JR, Anderson JL: Disposition of intravenous pirmenol. J Clin Pharmacol 1983;23:113-122.
7. Garg DC, Jallad NS, Singh S, Ng KF, Weidler DJ: Efficacy and pharmacokinetics of oral pirmenol, a new antiarrhythmic drug. J Clin Pharmacol 1988;28:812-817.
8. Janiczek N, Bockbrader HN, Chang T, Amidon GL, Smith DE: Stereoselective high-performance liquid chromatographic assay for pirmenol enantiomers in dog plasma. J Chromatogr 1991; 571:179-187.
9. Tozer TN, Gambertoglio JG, Furst DE, Avery DS, Holford NHG: Volume shifts and protein binding estimates using equilibrium dialysis: application to prednisolone binding in humans. J Pharm Sci 1983;72:1442-1446.
10. Pfeffer M: Estimation of mean residence time from data obtained when multiple-dosing steady state has been reached. J Pharm Sci 1984;73:854-856.
11. Lima JJ, Boudoulas H, Shields BJ: Stereoselective pharmacokinetics of disopyramide enantiomers in man. Drug Metab Dispos 1985;13:572-577.
12. Lima JJ, Wenzke SC, Boudoulas H, Schaal SF: Antiarrhythmic activity and unbound concentrations of disopyramide enantiomers in patients. Ther Drug Monit 1990;12:23-28.
13. Hasselstrom J, Enquist M, Hermansson J, Dahlquist R: Enantioselective steady-state kinetics of unbound disopyramide and its dealkylated metabolite in man. Eur J Clin Pharmacol 1991;41: 481-484.
14. Le Corre P, Gibassier D, Sado P, Le Verge R: Human pharmacokinetics and metabolism of disopyramide enantiomers. Eur J Drug Metab Pharmacokinet 1991; Spec. No. 3:233-239.
15. Thomson AH, Murdoch G, Pottage A, Kelman AW, Whiting B, Hillis WS: The pharmacokinetics of R- and S-tocainide in patients with acute ventricular arrhythmias. Br J Clin Pharmacol 1986;21:149-154.
16. Conings L, Verbeke N: Stereoselective pharmacokinetic behavior of tocainide enantiomers in man. Br J Clin Pharmacol 1986;89(suppl):701P.
17. McErlane KM, Axelson J, Vaughan R, Kerr CR, Price JD, Igwemezie L, Pillai G: Stereoselective pharmacokinetics of tocainide in human uraemic patients and in healthy subjects. Eur J Clin Pharmacol 1990;39;373-376.
18. Grech-Belanger O, Turgeon J, Gilbert M: Stereoselective disposition of mexiletine in man. Br J Clin Pharmacol 1986;21:481-487.
19. Gross AS, Mikus G, Fischer C, Hertrampf R, Gundert-Remy U: Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metabolizer phenotype. Br J Clin Pharmacol 1989;28:555-566.
20. Turgeon J, Funck-Brentano C, Grat HT, Pavlou HN, Prakash C, Blair IA, Roden DM: Genetically determined stereoselective excretion of encainide in humans and electrophysiologic effects of its enantiomers in canine cardiac Purkinje fibers. Clin Pharmacol Ther 1991;49:488-496.
21. Brode E, Muller-Peltzer H, Hollmann M: Comparative pharmacokinetics and clinical pharmacology of propafenone enantiomers after oral administration to man. Methods Find Exp Clin Pharmacol 1988;10(11):717-727.
22. Kroemer HK, Fromm MF, Buhl K, Terefe H, Blaschke G, Eichelbaum M: An enantiomer-enantiomer interaction of (S)- and (R)-propafenone modifies the effect of racemic drug therapy. Circulation 1994;89:2396-2400.
23. von Bahr C, Hermansson J, Tawara K: Plasma levels of (+) and (-)-propranolol and 4-hydroxypropranolol after administration of racemic (±)-propranolol in man. Br J Clin Pharmacol 1982;14:79-82.
24. Lalonde RL, Bottorff MB, Straka RJ, Tenero DM, Peiper JA, Wainer IW: Nonlinear accumulation of propranolol enantiomers. Br J Clin Pharmacol 1988;26:100-102.
25. Prakash C, Koshakji RP, Wood AJJ, Blair IA: Simultaneous determination of propranolol enantiomers in plasma by high-performance liquid chromatography with fluorescence detection. J Pharm Sci 1989;78(9):771-775.
26. Lalonde RL, Tenero DM, Burlew BS, Herring VL, Bottorff MB: Effects of age on the protein binding and disposition of propranolol stereoisomers. Clin Pharmacol Ther 1990;47:447-455.
27. Reiter MJ, Shand DG, Pritchett ELC: Comparison of intravenous and oral verapamil dosing. Clin Pharmacol Ther 1982; 32:711-720.
28. Eichelbaum M, Mikus G, Vogelgesang B: Pharmacokinetics of (+)-, (-)- and (±)verapamil after intravenous administration. Br J Clin Pharmacol 1984;17:453-458.
29. Vogelgesang B, Echizen H, Schmidt E, Eichelbaum M: Stereoselective first-pass metabolism of highly-cleared drugs: studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique. Br J Clin Pharmacol 1984;18:733-740.
30. Soons PA, Breimer DD: Stereoselective pharmacokinetics of oral and intravenous nitrendipine in healthy male subjects. Br J Clin Pharmacol 1991;32:11-16.
31. Mast V, Fischer C, Mikus G, Eichelbaum M: Use of pseudoracemic nitrendipine to elucidate the metabolic steps responsible for stereoselective disposition of nitrendipine enantiomers. Br J Clin Pharmacol 1992;33:51-59.
32. Winkle RA: The relationship between ventricular ectopic beat frequency and heart rate. Circulation 1982;66:439-446.
33. Toivonen L: Spontaneous variability in the frequency of ventricular premature complexes over prolonged intervals and implications for antiarrhythmic treatment. Am J Cardiol 1987;60:608-612.
34. Anastssiou-Nana MI, Menlove RL, Nanas JN, Anderson JL: Changes in spontaneous variability of ventricular ectopic activity as a function of time in patients with chronic arrhythmias. Circulation 1988;78:286-295.
35. Anderson JL, Anastssiou-Nana MI, Menlove RL, Moreno FL, Nanas JN, Barker AH: Spontaneous variability in ventricular ectopic activity during chronic antiarrhythmic therapy. Circulation 1990;82:830-840.
36. Holazo AA, Brazzell RK, Colburn WA: Pharmacokinetic and pharmacodynamic modeling of cibenzoline plasma concentrations and antiarrhythmic effect. J Clin Pharmacol 1986;26:336-345.
37. Bigger JT, Hoffman BF: Antiarrhythmic drugs. In. Gilman AG, Rall TW, Nies AS, Taylor P (eds.): Goodman and Gilman's The Pharmacological Basis of Therapeutics. Eighth Edition. New York: Pergamon Press, 1990;840-873.
38. Reiter MJ, Hammill SC, Shand DG, Verghese C, McCarthy E, Pritchett ELC: Efficacy, safety, and pharmacokinetics of a concentration-maintaining regimen of intravenous pirmenol. Am J Cardiol 1983;52:83-87.
39. Anderson JL, Lutz JR, Nappi JM: Pirmenol for control of ventricular arrhythmias: oral dose-ranging and short-term maintenance study. Am J Cardiol 1984;53:522-527.
40. Toivonen LK, Nieminen MS, Manninen V, Frick MH: Antiarrhythmic efficacy of pirmenol in the treatment of premature ventricular complexes. Eur Heart J 1985;6:737-744.
41. Toivonen LK, Nieminen MS, Manninen V, Frick MH: Pirmenol in the long-term treatment of chronic ventricular arrhythmias: a placebo-controlled study. J Cardiovasc. Pharmacol 1986; 8:156-160.
42. Farnham DJ: A multicenter dose-response study of pirmenol hydrochloride in patients with ventricular premature contractions. Am J Cardiol 1987;59:43H-47H.
43. Ellenbogen KA, Roark SF, Sintetos AL, Smith MS, McCarthy EA, Smith WM, et al: Pharmacodynamics and pharmacokinetics of oral pirmenol. Clin Pharmacol Ther 1987;42:405-410.
44. Johnson BF, Haffajee CI, Woodman T, Sloan KL: The relation of the kinetics of pirmenol to its antiarrhythmic efficacy. J Clin Pharmacol 1988;28:401-405.